Secondary Prevention of Coronary Disease with ACE Inhibition-does Blood Pressure Reduction with Perindopril Explain the Benefits in EUROPA?

By Remme Willem   Deckers Jaap   Fox Kim   Ferrari Roberto   Bertrand Michel   Simoons Maarten  

Cardiovascular Drugs and Therapy, Vol. 23, Iss. 2, 2009-04 ,pp. : 161-170

Springer Publishing Company

Access to resources Recommend Favorite

The Rationale and Design of the Perindopril Genetic Association Study (PERGENE): A Pharmacogenetic Analysis of Angiotensin-Converting Enzyme Inhibitor Therapy in Patients with Stable Coronary Artery Disease

By Brugts J.   Maat M.   Boersma E.   Witteman J.   Duijn C.   Uitterlinden A.   Bertrand M.   Remme W.   Fox K.   Ferrari R.   Danser A.   Simoons M.  

Cardiovascular Drugs and Therapy, Vol. 23, Iss. 2, 2009-04 ,pp. : 171-181

Springer Publishing Company

Access to resources Recommend Favorite

Cardiovascular Outcomes and Angiotensin Converting Enzyme Inhibitors: Beyond Blood Pressure Control: Editorial to: “Secondary Prevention of Coronary Disease with ACE Inhibition—Does Blood Pressure Reduction with Perindopril Explain the Benefits in EUROPA?” by Remme et al.

By Verma Anil   Ventura Hector  

Cardiovascular Drugs and Therapy, Vol. 23, Iss. 2, 2009-04 ,pp. : 109-111

Springer Publishing Company

Access to resources Recommend Favorite

Intervention with Clarithromycin in Patients with Stable Coronary Heart Disease

By  

Heart Drug, Vol. 1, Iss. 1, 2001-03 ,pp. : 14-19

Karger

Access to resources Recommend Favorite

Perindopril is beneficial among patients with stable coronary artery disease who are receiving calcium channel blockers

By  

Inpharma, Vol. 1, Iss. 1654, 2008-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite